US Edition
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing - Biogen (NASDAQ:BIIB)
NORTH CAROLINA, JUL 21 – Biogen will invest $2 billion to expand and modernize its North Carolina manufacturing with advanced automation and AI to support its late-stage clinical pipeline, adding to $10 billion invested to date.
- On Monday, July 21, 2025, Biogen announced a $2 billion investment in RTP manufacturing, including an eighth factory expected to begin operation in the second half of 2025.
- With potential U.S. import levies looming, Biogen’s 30-year RTP track record led it to expand its footprint, with $10 billion invested to date, and President Donald Trump indicated tariffs could come as soon as August 1.
- Biogen plans to enhance operations by upgrading its RTP facilities through antisense oligonucleotide manufacturing, establishing multi-platform fill-finish, and modernizing manufacturing technologies with advanced automation and artificial intelligence.
- Highlighting local jobs, Nicole Murphy, head of pharmaceutical operations and technology at Biogen, said, 'With this investment, we will modernize and expand our manufacturing capability to enable our pipeline and provide resilient patient supply.'
- Industry forecasts show that in the next few years, Biogen joins the industry trend of over $200 billion in new and renovated facilities, indicating long-term sector growth.
18 Articles
18 Articles
Colorado Springs Gazette
Biogen expanding to keep pace with modernization, artificial intelligence
(The Center Square) – Modernization of “manufacturing technologies and controls through further advanced automation and artificial intelligence” are helping trigger Biogen’s commitment of $2 billion into its North Carolina facilities. The Fortune 500 company based in Cambridge, Mass., opened its…
Beacon Investment Advisory Services Inc. Sells 3,529 Shares of Biogen Inc. (NASDAQ:BIIB)
Beacon Investment Advisory Services Inc. cut its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 18.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,080 shares of the biotechnology company's stock after selling 3,529 sha
Biogen beefs up North Carolina manufacturing ahead of potential Trump tariff
Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as it seeks to expand in the U.S. amid President Donald Trump's tariff threats.
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing - Biogen (NASDAQ:BIIB)
Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline. In the next f…
Coverage Details
Bias Distribution
- 43% of the sources lean Left, 43% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
